| Literature DB >> 19473478 |
Matilda Larsson1, Anna Bjällmark, Jonas Johnson, Reidar Winter, Lars-Ake Brodin, Stig Lundbäck.
Abstract
BACKGROUND: Cardiac time intervals have been described as a measure of cardiac performance, where prolongation, shortening and delay of the different time intervals have been evaluated as markers of cardiac dysfunction. A relatively recently developed method with improved ability to measure cardiac events is Tissue Doppler Imaging (TDI), allowing accurate measurement of myocardial movements.Entities:
Mesh:
Year: 2009 PMID: 19473478 PMCID: PMC2693107 DOI: 10.1186/1476-7120-7-22
Source DB: PubMed Journal: Cardiovasc Ultrasound ISSN: 1476-7120 Impact factor: 2.062
Figure 1Definition of cardiac phases. Typical tissue Doppler imaging echocardiography-derived velocity profiles. a) Definition of cardiac phases in a velocity curve containing typical biphasic pattern with a negative and a positive velocity spike during Pre-Ejection and Post-Ejection. b and c) Definition of cardiac phases in a velocity curve containing only one zero-crossing during Pre-Ejection and Post-Ejection.
Figure 2Visual interpretation of the state diagram. One heart beat corresponds to all 360° in the state diagram, starting with Pre-Ejection and ending with Atrial Contraction. The state diagram contains regional information from seven positions in the heart and global information represented by the mean time intervals. The outermost circular segment in the state diagram corresponds to the antero-septal wall, followed by the anterior, antero-lateral, infero-lateral, inferior, infero-septum (LV) and medial wall (RV). The global function of the left ventricle was an average of six measuring points, while the only measuring point in the right ventricle represented regional function.
Figure 3State diagrams in case examples. a) State diagram in a healthy subject b) State diagram in an athlete. c) State diagram in a subject with ischemia. d) State diagram in a subject with cardiac dyssynchrony.
Patient characteristic
| Subject | Age | Gender | HR | Clinical features | Medications |
| NSTEMI | 49 | male | 65 | Hypertension, hyperlipidemia | ASA, Clopidogrel, betablocker, statin, calcium antagonist |
| NSTEMI | 53 | male | 70 | Smoker, hypertension, hyperlipidemia | ASA, ACE1, Clopidogrel, betablocker, statin, calcium antagonist, diuretics |
| NSTEMI | 55 | female | 63 | Smoker, psoriasis | ASA, Clopidogrel, betablocker, statin |
| NSTEMI | 56 | male | 61 | Smoker | ASA, Clopidogrel, betablocker, statin |
| NSTEMI | 60 | male | 59 | Renal failure | ASA, Clopidogrel, statin, |
| NSTEMI | 63 | male | 56 | Smoker, hypertension | ASA, Clopidogrel, betablocker, statin, ACE-inhibitor, |
| NSTEMI | 72 | male | 53 | Diabetes II | ASA, Clopidogrel, betablocker, statin, ACE-inhibitor, Metforminen, Glibenclamide |
| Control | 49 | male | 60 | Ex-smoker, hypertension, diabetes II | ASA, ACE1, betablocker, calcium antagonist, metformine |
| Control | 52 | male | 59 | Myeloma | Talidomide, steroids, ASA |
| Control | 54 | female | 57 | Diabetes II, Bypass 2004 | Statin, betablocker, calcium antagonist, metformine |
| Control | 59 | male | 71 | Hypertension, liver cirrosis | - |
| Control | 62 | male | 66 | Ex-smoker, hypothyreosis | Levaxine |
| Control | 62 | male | 70 | Atrial fibrillation | Betablocker |
| Control | 73 | male | 54 | - | - |
Patient characteristic for the NSTEMI group and their matched controls.
Comparison of mean percentage duration (%) in cardiac phases between the NSTEMI group and the control group
| Left ventricle | Right ventricle | |||||
| NSTEMI group mean (SD) | Control group mean (SD) | Difference mean (SD) | NSTEMI group mean (SD) | Control group mean (SD) | Difference mean (SD) | |
| Pre-Ejection | 8.26 (1.4) | 4.73 (1.05) | -3.52 (1.5)** | 6.49 (1.5) | 4.31 (1.5) | -2.18 (2.2)* |
| Early Ventricular Ejection | 6.02 (1.4) | 6.55 (1.8) | 0.53 (1.5) | 5.98 (1.4) | 6.00 (1.9) | 0.02 (2.2) |
| Mid Ventricular Ejection | 8.12 (1.5) | 9.07 (0.8) | 0.95 (2.0) | 7.52 (1.2) | 9.61 (1.2) | 2.09 (2.1)* |
| Late Ventricular Ejection | 15.31 (1.5) | 15.16 (2.4) | -0.15 (2.5) | 16.78 (1.8) | 15.21 (2.7) | -1.57 (4.0) |
| Post-Ejection | 9.46 (2.2) | 6.76 (2.1) | -2.70 (2.5)* | 8.45 (2.2) | 5.51 (1.2) | -2.94 (1.5)** |
| Early Rapid Filling | 6.60 (0.9) | 8.25 (1.5) | 1.65 (1.5)* | 8.08 (1.3) | 8.83 (2.0) | 0.75 (1.6) |
| Late Rapid Filling | 10.49 (1.3) | 10.64 (1.4) | 0.15 (2.2) | 11.46 (3.3) | 11.52 (2.0) | 0.06 (4.13) |
| Slow Filling | 23.13 (6.0) | 23.25 (4.2) | 0.12 (9.1) | 21.14 (4.4) | 21.66 (4.3) | 0.52 (8.3) |
| Early Atrial Contraction | 7.12 (0.5) | 7.85 (0.8) | 0.73 (1.2) | 7.46 (0.9) | 8.32 (1.8) | 0.86 (1.6) |
| Late Atrial Contraction | 5.47 (1.1) | 7.74 (0.8) | 2.27 (1.5) ** | 6.63 (1.3) | 9.03 (0.8) | 2.40 (1.6)** |
The mean percentage duration (%) of each phase is displayed with its standard deviation for both the groups and the ventricles. The right column for both ventricles contains differences in percentage distribution of the phases in the state diagram between the NSTEMI group and the control group. The level of significance is illustrated with annotations (* p < 0.05, ** p < 0.005).
Figure 4Comparison between the NSTEMI group and the control group. Global state diagram for the NSTEMI group and the control group. The mean percentage of duration for the phases is displayed with corresponding level of significance for each group.
Comparison of echocardiographic variables between the NSTEMI group and the control group
| NSTEMI group mean (SD) | Control group mean (SD) | Difference mean (SD) | |
| E/E' ratio | 13.66 (4.6) | 10.51 (4.4) | -3.15 (6.2) |
| LVEF (%) | 57.57 (12.2) | 59.00 (4.9) | 1.43 (9.9) |
| WSMI | 1.20 (0.3) | 1.01 (0.0) | -0.19 (0.3) |
The table displays the mean and the mean difference in E/E' ratio, left ventricular Ejection Fraction (LVEF) and wall motion score index (WMSI), with the standard deviation for the NSTEMI group and the control group.